Contemporary Clinical Trials Communications (Mar 2021)

Prescribed exercise to Reduce Recidivism After Weight Loss-Pilot (PREVAIL-P): Design, methods and rationale

  • Damon L. Swift,
  • Joshua E. McGee,
  • Anna C. Huff,
  • Marie C. Clunan,
  • Nicole R. Gniewek,
  • Taylor T. Brown,
  • Briceida G. Osborne,
  • Colleen Bucher,
  • Charles J. Tanner,
  • Savanna G. Barefoot,
  • Patricia Brophy,
  • Angela Clark,
  • Gabriel S. Dubis,
  • Corby K. Martin,
  • Robbie A. Beyl,
  • Joseph A. Houmard,
  • Robert A. Carels,
  • Walter Pories,
  • Laura E. Matarese

Journal volume & issue
Vol. 21
p. 100717

Abstract

Read online

Clinically significant weight loss is associated with health benefits for overweight and obese adults. Participation in adequate amounts of physical activity is critical for weight maintenance. However, the recommended amount of physical activity needed to promote weight maintenance is based primarily on retrospective studies that quantified physical activity levels through questionnaires which tend to overestimate physical activity levels. In addition, the present literature has provided little data on the impact of these physical activity levels on cardiovascular and diabetes risk factors, which may have equal or more clinical importance than weight changes. The Prescribed Exercise to Reduce Recidivism After Weight Loss-Pilot (PREVAIL-P) study will evaluate the effect of aerobic exercise training amount on weight maintenance following clinically significant weight loss in overweight and obese adults (BMI 25–40 kg/m2) age 30–65 years. Participants (N = 39) will complete a 10-week OPTIFAST® weight loss program with supervised aerobic exercise training. Individuals who achieve ≥7% weight loss from baseline will be subsequently randomized to levels of aerobic training consistent with physical activity recommendations (PA-REC) or weight maintenance recommendations (WM-REC) for 18 additional weeks. The primary outcome of the PREVAIL-P study will be change in weight from the completion of OPTIFAST® program to the end of the study. Notable secondary measures include changes in clinically relevant cardiometabolic risk factors between study groups (e.g. blood lipids concentrations, oral glucose tolerance, arterial stiffness). This pilot study will be used to estimate the effect sizes needed for a randomized controlled trial on this topic.

Keywords